We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Arecor Therapeutics Plc | LSE:AREC | London | Ordinary Share | GB00BMWLM973 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -1.00 | -1.98% | 49.50 | 44,675 | 13:17:35 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 48.00 | 51.00 | 50.50 | 49.00 | 50.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 5.72M | -8.55M | -0.2266 | -2.18 | 19.07M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 14:22:32 | O | 1,010 | 49.47 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 12/3/2025 | 15:34 | ALNC |  Arecor Therapeutics strikes deal for development of peptide therapy |
| 12/3/2025 | 07:00 | UK RNS | Arecor Therapeutics PLC Arecor partnership with biopharmaceutical company |
| 03/2/2025 | 13:28 | ALNC | Arecor Therapeutics confident for the future as revenue rises |
| 03/2/2025 | 07:00 | UK RNS | Arecor Therapeutics PLC Arecor Full Year 2024 Trading Update |
| 10/1/2025 | 21:21 | ALNC | IN BRIEF: Arecor Therapeutics shares tumble as plans Tetris wind-down |
| 10/1/2025 | 07:45 | UK RNS | Arecor Therapeutics PLC Orderly Cessation of Tetris Pharma Operations |
| 09/1/2025 | 07:00 | UK RNS | Arecor Therapeutics PLC Change of Nominated Advisor and Joint Broker |
| 30/12/2024 | 11:44 | ALNC | IN BRIEF: Arecor Therapeutics signs new drug licensing agreement |
| 30/12/2024 | 07:00 | UK RNS | Arecor Therapeutics PLC Arecor Signs Exclusive Licensing Agreement |
| 02/12/2024 | 07:00 | UK RNS | Arecor Therapeutics PLC Grant of Options and PDMR Dealing |
Arecor Therapeutics (AREC) Share Charts1 Year Arecor Therapeutics Chart |
|
1 Month Arecor Therapeutics Chart |
Intraday Arecor Therapeutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 14/3/2025 | 10:48 | Arecor | 334 |
| 27/2/2024 | 09:01 | Current weakness | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 16/3/2025 08:20 by Arecor Therapeutics Daily Update Arecor Therapeutics Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker AREC. The last closing price for Arecor Therapeutics was 50.50p.Arecor Therapeutics currently has 37,756,601 shares in issue. The market capitalisation of Arecor Therapeutics is £18,689,517. Arecor Therapeutics has a price to earnings ratio (PE ratio) of -2.18. This morning AREC shares opened at 50.50p |
Posted at 17/2/2025 15:38 by stupidboypike Jonesy, I could not agree more, I too am furious, good tech, terrible business acumen. I also held HYG from when it was launched but sold a long time ago. I bought AREC shares before the IPO and many more after. Half of me wants to sell all my AREC shares, but the other part thinks the tech is good, patented, and should at some point reward shareholders. The frustrating thing now is that an offer for the company at 70p would almost certainly succeed and all those years of patience count for nothing. I REALLY hope the co-development deal for AT278 turns this around, but based on history so far I am not at all confident of that. Bah humbug!Best regards SBP |
Posted at 10/1/2025 11:16 by stupidboypike So just 6 months ago this is what they said for the fundraise:-i. £2.7 million - continue to invest in Arecor research and development with a focus on delivering enhanced injectables and oral-GLP-1 data packages to convert value driving partnering, working capital. ii. £2.7 million - investment in Tetris Pharma to drive Ogluo® product sales through investment in inventory and in awareness and marketing campaigns in the UK and Germany with the aim to reach cashflow positive in 2026. So we hope and pray that they haven't spent much of the 2.7m on Tetris. If they haven't then they probably (only?!!) need another £2m for the AT278 trial. My best guess a £3m fund raise at 60p a share in the next month or two. Share price will no doubt tell us the fund raise price in advance of it happening! Best regards SBP |
Posted at 13/12/2024 14:12 by stupidboypike The share price decline continues and frankly it is difficult to see what would slow that down other than a cracking deal on a trial with the next AT278 trial. How they will get that when they are insisting on non-exclusive is beyond me. I am becoming increasingly frustrated at Arecor. If I had any sense I would probably get rid of half my holding, but it does appear that in the fullness of time it could come good, so I am hanging on. May well regret that!!!Best regards SBP |
Posted at 23/10/2024 08:54 by stupidboypike Jonesy,Yes I agree, despite my huge frustration over the share price and the way the financing/PR has been managed over the last few months, I do think Arecor is a winner. The technology clearly delivers something unique into a market worth many billions. I have a reasonable holding and don't plan on parting with any of them until a decent portion of that value comes out. A half decent deal on the next trial with AT278 could completely transform the market perception of Arecor. Here's hoping! Best regards SBP |
Posted at 16/10/2024 16:10 by stupidboypike The two "sells" of 9850 shares were a sale and purchase into my isa. (Nice to see the share price nudging up for once.)Best regards SBP |
Posted at 04/10/2024 01:55 by stupidboypike I worry that in hanging on for the very best deal, the share price will drop so low (even lower than now!!) and make us vulnerable to a cheap takeover.Best regards SBP |
Posted at 03/10/2024 14:08 by stupidboypike If anyone is on the webinar, I have just asked the following question:"What plans do the company have in light of the fact that the recent fund raise only raised enough cash for 24 months. As we have seen by the share price reaction, the market hates a company that is losing money and in constant need of funds. Is it hoped that a deal with AT278 will produce the long awaited "value inflexion point" that will shore up the cashflow within that 24 month window?" If anyone else is on the webinar and would like the answer please vote it up. Best regards SBP |
Posted at 24/9/2024 07:44 by jonesy100 There is an AREC results presentation being hosted by LSE on Thursday. Maybe we will find out then whether there is something badly wrong. |
Posted at 09/8/2024 08:01 by nchanning Like the tech here but as always on AIM the cash runway is still too tight ( 2 years optimistically) after the placing . What's going to happen in a year again ? The share price is going to tank fearing another discounted placing which will then cause big dilution to raise another meagre cash pile |
Posted at 04/12/2023 13:16 by 127tolmers As foreshadowed in the TD report which calculated potential values of such a deal:Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces a co-development and exclusive licence option agreement with a leading global medical products company for a high-value, ready-to-dilute (“RTD”) oncology product from Arecor’s in-house Specialty Hospital pipeline. Under the terms of the agreement, Arecor and its partner will conduct further co-development and regulatory work with Arecor eligible to receive potential developmental milestones. The agreement includes an option for the partner to be granted an exclusive, worldwide license to further develop and commercialise the product, with Arecor eligible to receive milestones and royalty payments. Arecor has developed a proprietary RTD form of a lyophilized powder product using its formulation technology platform, Arestat™. This novel, liquid, RTD formulation of an existing ‘blockbuster&# |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
